TY - JOUR
T1 - Effects of pentoxifylline on inflammatorymarkers and blood pressure
T2 - A systematic reviewandmeta-analysis of randomized controlled trials
AU - Brie, D.
AU - Sahebkar, Amirhossein
AU - Penson, P.E.
AU - Dinca, M.
AU - Ursoniu, S.
AU - Serban, M.C.
AU - Zanchetti, A.
AU - Howard, G.
AU - Ahmed, A.
AU - Aronow, W.S.
AU - Muntner, P.
AU - Lip, G.Y.H.
AU - Wong, N.D.
AU - Rysz, J.
AU - Banach, M.
PY - 2016
Y1 - 2016
N2 - Copyright © 2016 Wolters Kluwer Health, Inc.Introduction: Pentoxifylline is a xanthine derivative with potential cardiovascular benefits. Aim: To evaluate the impact of pentoxifylline on blood pressure (BP) and plasma TNF-α, C-reactive protein (CRP) and IL-6 through a systematic review and meta-analysis of randomized controlled trials. Methods: The protocol was registered (PROSPERO: CRD42016035988). The search included PUBMED, ProQuest, Scopus and EMBASE until 1 September 2015 to identify trials reporting BP or inflammatory markers during pentoxifylline therapy. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WDF) and 95% confidence intervals (CIs) as summary statistics. Results: Fifteen studies (16 treatment arms) were found to be eligible for inclusion. Meta-analysis did not suggest any effect of pentoxifylline on either SBP or DBP. Pentoxifylline treatment was associated with a significant reduction in plasma concentrations of TNF-α (WDF: -1.03 pg/ml, 95% CI: -1.54, -0.51; P
AB - Copyright © 2016 Wolters Kluwer Health, Inc.Introduction: Pentoxifylline is a xanthine derivative with potential cardiovascular benefits. Aim: To evaluate the impact of pentoxifylline on blood pressure (BP) and plasma TNF-α, C-reactive protein (CRP) and IL-6 through a systematic review and meta-analysis of randomized controlled trials. Methods: The protocol was registered (PROSPERO: CRD42016035988). The search included PUBMED, ProQuest, Scopus and EMBASE until 1 September 2015 to identify trials reporting BP or inflammatory markers during pentoxifylline therapy. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WDF) and 95% confidence intervals (CIs) as summary statistics. Results: Fifteen studies (16 treatment arms) were found to be eligible for inclusion. Meta-analysis did not suggest any effect of pentoxifylline on either SBP or DBP. Pentoxifylline treatment was associated with a significant reduction in plasma concentrations of TNF-α (WDF: -1.03 pg/ml, 95% CI: -1.54, -0.51; P
U2 - 10.1097/HJH.0000000000001086
DO - 10.1097/HJH.0000000000001086
M3 - Article
SN - 0263-6352
VL - 34
SP - 2318
EP - 2329
JO - Journal of Hypertension
JF - Journal of Hypertension
IS - 12
ER -